Pure Global AI
NCT06212128Recruitment Completed

RAPIDO vs LCRT vs Upfront Surgery - a Prospective Cohort Study

Novel Objective Comparison of Short-term Surgical Outcomes From Total Mesorectal Excision Between Total Neoadjuvant Therapy - Rapido Protocol, Standard Long Course Radiotherapy and Upfront Surgery
Sengkang General HospitalClinicalTrials.govcombination product
Verified
Study focus
Disease/Condition
Rectal Cancer
Drug/Device/Intervention
RAPIDO TNT
Study type
Observational
Intervention type
combination product
Sponsor & location
Primary sponsor
Sengkang General Hospital
Timeline & enrollment
Phase
N/A
Start date
Jan 01, 2016
End date
Jun 30, 2024
Enrollment
57 participants
Primary outcome

operative time required for primary resection of rectal tumour

Summary

Aim: We evaluated the surgical outcomes of 3 groups of patients with rectal cancers - RAPIDO
 vs standard long course radiotherapy (LCRT) vs upfront surgery to objectively determine the
 effects of TNT on TME.
 
 Methods: A review of prospectively collected data was performed for patients who have rectal
 cancer and underwent low anterior resection from January 2016 to May 2022. Data on patient
 demographics, disease staging, peri-operative details and up to 2-year follow-up outcomes
 were analysed. The surgical and oncological outcomes were compared. Patients were followed up
 until 31 May 2022.

ICD-10 classifications
Malignant neoplasm of rectumCarcinoma in situ: RectumBenign neoplasm: RectumSecondary malignant neoplasm of large intestine and rectumCarcinoma in situ: Rectosigmoid junction
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06212128
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06212128 through Pure Global AI's free database. This phase not specified trial is sponsored by Sengkang General Hospital and is currently Recruitment Completed. The study focuses on Rectal Cancer. Target enrollment is 57 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.